ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
NCT00662597
Terminated
The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: Breslin Cancer Center, Lansing, Michigan +1 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
NCT01268059
Terminated
The purpose of this study is to evaluate the dose, antitumor activity, safety and pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with previously untreated, advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/01/2020
Locations: Research Site, Detroit, Michigan
Conditions: Non-small Cell Lung Cancer
Register for Updates
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
NCT02106546
Completed
The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/13/2020
Locations: Henry Ford Health System /ID# 126500, Detroit, Michigan +1 locations
Conditions: Squamous Non-Small Cell Lung Cancer
Register for Updates
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
NCT01051570
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving carboplatin together with everolimus and prednisone may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving carboplatin togeth... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
11/06/2020
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan +1 locations
Conditions: Prostate Cancer
Register for Updates
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
NCT03704467
Completed
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/21/2020
Locations: Covenant Health Care, Saginaw, Michigan
Conditions: Ovarian Cancer
Register for Updates
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
NCT00576225
Withdrawn
This study is designed to test whether CT-2103/carboplatin provides improved overall survival compared to paclitaxel/carboplatin in women with NSCLC who have estradiol levels \>30 pg/ml.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/14/2020
Locations: Henry Ford Health System, Josephine Ford Cancer Center, Detroit, Michigan +1 locations
Conditions: NSCLC
Register for Updates
Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00054210
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of chemotherapy is more effective in treating stage IIIB, stage IV, or recurrent non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of polyglutamate paclitaxel plus carboplatin to that of paclitaxel plus carboplatin in treating patients who have s... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/02/2020
Locations: Not set, Grand Rapids, Michigan
Conditions: Lung Cancer
Register for Updates
Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00551733
Terminated
RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, and paclitaxel poliglumex, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving carboplatin together with paclitaxel poliglumex is more effective than giving carboplatin together with paclitaxel in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel poliglume... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
10/02/2020
Locations: West Michigan Regional Cancer and Blood Center, Free Soil, Michigan +1 locations
Conditions: Lung Cancer
Register for Updates
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
NCT02476955
Terminated
An Open-label Phase 1b Study of ARQ 092 in Combination with other Antineoplastic Agents in Subjects with Selected Solid Tumors
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/28/2020
Locations: Not set, Grand Rapids, Michigan
Conditions: Solid Tumors, Ovarian Cancer, Endometrial Cancer
Register for Updates
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
NCT00625898
Terminated
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/09/2020
Locations: Bixby Medical Center, Adrian, Michigan +44 locations
Conditions: Breast Cancer
Register for Updates
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
NCT01859741
Terminated
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 (tarextumab) in combination with etoposide (EP) for 6 cycles followed a Phase 2, multi center, randomized, placebo-controlled portion comparing the efficacy and safety of OMP-59R5 in combination with EP for 6 cycles followed by single agent OMP-59R5 relative to EP alone for 6 cycles in subjects receiving first-line therapy for extensive stage small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
09/07/2020
Locations: University of Michigan Medical Center, Clinical Trials Office, Ann Arbor, Michigan +1 locations
Conditions: Stage IV Small Cell Lung Cancer
Register for Updates
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
NCT02259582
Completed
A randomized, double-blind, 3-arm (1:1:1) study in subjects with first-line Stage IV non-squamous NSCLC. The purpose is to test the efficacy and safety of demcizumab, when given in combination with carboplatin and pemetrexed compared to placebo. The administration of carboplatin and pemetrexed is a standard treatment for patients with non-squamous non-small cell lung cancer.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
09/07/2020
Locations: Henry Ford Health System, Detroit, Michigan +1 locations
Conditions: Nonsquamous Nonsmall Cell Neoplasm of Lung
Register for Updates